vs
Side-by-side financial comparison of MEDALLION FINANCIAL CORP (MFIN) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
MEDALLION FINANCIAL CORP is the larger business by last-quarter revenue ($70.6M vs $57.3M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). MEDALLION FINANCIAL CORP runs the higher net margin — 17.3% vs -83.0%, a 100.3% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 25.4%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 15.0%).
Mahindra & Mahindra Financial Services Limited (MMFSL) is an Indian rural non-banking financial company headquartered in Mumbai. It is amongst the top tractor financers in India, with 1000+ offices across the country.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
MFIN vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $70.6M | $57.3M |
| Net Profit | $12.2M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 29.3% | -82.2% |
| Net Margin | 17.3% | -83.0% |
| Revenue YoY | 25.4% | 36.9% |
| Net Profit YoY | 20.3% | -9.6% |
| EPS (diluted) | $0.50 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $70.6M | $57.3M | ||
| Q3 25 | $58.7M | $51.3M | ||
| Q2 25 | $62.6M | $48.5M | ||
| Q1 25 | $63.0M | $32.7M | ||
| Q4 24 | $56.3M | $41.8M | ||
| Q3 24 | $53.3M | $33.3M | ||
| Q2 24 | $51.0M | $29.1M | ||
| Q1 24 | $53.3M | $26.0M |
| Q4 25 | $12.2M | $-47.5M | ||
| Q3 25 | $7.8M | $-52.9M | ||
| Q2 25 | $11.1M | $-46.6M | ||
| Q1 25 | $12.0M | $-49.5M | ||
| Q4 24 | $10.1M | $-43.3M | ||
| Q3 24 | $8.6M | $-43.6M | ||
| Q2 24 | $7.1M | $-32.3M | ||
| Q1 24 | $10.0M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 29.3% | -82.2% | ||
| Q3 25 | 33.2% | -102.6% | ||
| Q2 25 | 31.1% | -93.4% | ||
| Q1 25 | 32.1% | -143.7% | ||
| Q4 24 | 32.8% | -98.6% | ||
| Q3 24 | 26.6% | -132.0% | ||
| Q2 24 | 24.3% | -139.2% | ||
| Q1 24 | 33.6% | -538.7% |
| Q4 25 | 17.3% | -83.0% | ||
| Q3 25 | 13.2% | -103.1% | ||
| Q2 25 | 17.7% | -96.1% | ||
| Q1 25 | 19.1% | -151.4% | ||
| Q4 24 | 18.0% | -103.6% | ||
| Q3 24 | 16.1% | -131.2% | ||
| Q2 24 | 13.9% | -110.9% | ||
| Q1 24 | 18.8% | -544.4% |
| Q4 25 | $0.50 | $-0.73 | ||
| Q3 25 | $0.32 | $-0.82 | ||
| Q2 25 | $0.46 | $-0.75 | ||
| Q1 25 | $0.50 | $-0.81 | ||
| Q4 24 | $0.43 | $-0.71 | ||
| Q3 24 | $0.37 | $-0.73 | ||
| Q2 24 | $0.30 | $-0.55 | ||
| Q1 24 | $0.42 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.3M | $388.9M |
| Total DebtLower is stronger | $216.0M | — |
| Stockholders' EquityBook value | $408.6M | $139.1M |
| Total Assets | $3.0B | $480.2M |
| Debt / EquityLower = less leverage | 0.53× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $136.3M | $388.9M | ||
| Q3 25 | $72.5M | $416.1M | ||
| Q2 25 | $110.4M | $291.0M | ||
| Q1 25 | $131.5M | $314.5M | ||
| Q4 24 | $98.2M | $320.6M | ||
| Q3 24 | $120.6M | $298.4M | ||
| Q2 24 | $87.7M | $319.1M | ||
| Q1 24 | $54.8M | $201.2M |
| Q4 25 | $216.0M | — | ||
| Q3 25 | $215.7M | — | ||
| Q2 25 | $199.9M | — | ||
| Q1 25 | $199.7M | — | ||
| Q4 24 | $232.2M | — | ||
| Q3 24 | $232.0M | — | ||
| Q2 24 | $230.8M | — | ||
| Q1 24 | $225.6M | — |
| Q4 25 | $408.6M | $139.1M | ||
| Q3 25 | $397.4M | $148.8M | ||
| Q2 25 | $389.9M | $-11.9M | ||
| Q1 25 | $380.2M | $18.9M | ||
| Q4 24 | $370.2M | $21.7M | ||
| Q3 24 | $362.4M | $11.2M | ||
| Q2 24 | $354.0M | $39.3M | ||
| Q1 24 | $349.0M | $61.6M |
| Q4 25 | $3.0B | $480.2M | ||
| Q3 25 | $2.9B | $506.9M | ||
| Q2 25 | $2.9B | $372.7M | ||
| Q1 25 | $2.8B | $386.7M | ||
| Q4 24 | $2.9B | $392.3M | ||
| Q3 24 | $2.9B | $363.6M | ||
| Q2 24 | $2.8B | $381.8M | ||
| Q1 24 | $2.6B | $258.7M |
| Q4 25 | 0.53× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 0.63× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.65× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $126.3M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 10.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $126.3M | $-25.4M | ||
| Q3 25 | $67.0M | $-26.6M | ||
| Q2 25 | $-10.7M | $-23.3M | ||
| Q1 25 | $36.3M | $-40.4M | ||
| Q4 24 | $108.7M | $-18.8M | ||
| Q3 24 | $24.6M | $-25.2M | ||
| Q2 24 | $27.6M | $-29.1M | ||
| Q1 24 | $32.3M | $-40.7M |
| Q4 25 | 10.35× | — | ||
| Q3 25 | 8.63× | — | ||
| Q2 25 | -0.97× | — | ||
| Q1 25 | 3.02× | — | ||
| Q4 24 | 10.72× | — | ||
| Q3 24 | 2.86× | — | ||
| Q2 24 | 3.89× | — | ||
| Q1 24 | 3.22× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
